Chargeurs

Holding Companies / France

New protective equipment activity to help offset Coronavirus impact

Latest - 14/04/2020

Chargeurs' new initiative, focused on the development and production of personal protective equipment (PPE), will allow the group to leverage the expertise of its PCC Fashion Technologies division to meet rising demand given the current global sanitary crisis caused by the Coronavirus. Acknowledging any potential execution risks given the volatile context, the new business line would allow Chargeurs to help off-set the expected hit to the group's core activities brought by the ongoing crisis.

Fact

- Under the brand Lainière Santé, Chargeurs will be launching a line of PPE products, including masks, scrubs, protective gloves, etc.
- The group will invest in production lines in France, the US and other geographies to assure mass production on a global scale.
- Given the current volatile environment, the group has yet to confirm the expected level of demand and sales potential of this new activity.

Analysis

In the context of the sanitary crisis brought by the Coronavirus outbreak, Chargeurs, like many industrial conglomerates, faces a challenging outlook due to the major disruption that has prompted a global economic crisis.

With an historical know-how in the textiles business, housed under the PCC Technologies division, last week's announcement of the launch of a new business line for the development and mass production PPE products, under the banner 'Laninière Santé', puts in evidence that Chargeurs' management has been quick-witted in assuring the continuity of its activities in the current market environment.

The group will be leveraging the expertise, production capacity and supplier network of its PCC Fashion Technologies division for the development of this new activity. The group's global footprint would allow it to secure orders from major customers including governments and large private institutions. Nonetheless, major efforts in logistics and distribution networks are needed in order to meet the skyrocketing demand for PPE products.

Subject to any execution risks that may transpire by the launch of a major industrial effort in this volatile market environment, and dependent on the evolution of demand, the new business line would partly off-set the decline in Chargeurs' core activities. It appears investors are confident in the management's skill in facing the crisis, given the remarkable share price recovery over the past 10 days with the Chargeurs share returning to its pre-Coronavirus price levels.

Impact

We will incorporate the new business line into our forecasts. Nonetheless, despite the positive contribution from Laninière Santé, we hold the view that, globally, the group's activities will be significantly disrupted by the ongoing Coronavirus crisis, resulting in an overall negative effect for FY2020.



Jorge VELANDIA otherfinancials@alphavalue.eu +33 (0) 1 70 61 10 50 cs.alphavalue.com

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Buy	Upside: 78.9%
Target Price (6 months)	€ 30.5
Share Price	€ 17.0
Market Cap. €M	394
Price Momentum	GOOD
Extremes 12Months	8.71 🕨 18.8
Bloomberg	CRI FP Equity
Reuters	CRIP.PA



Company Page



PERF	1 w	1m	3m	12m
Chargeurs	95.4%	43.7%	-1.50%	-2.00%
Other financials	9.48%	-1.81%	-17.0%	-0.79%
STOXX 600	6.32%	-1.14%	-20.9%	-14.0%

Last updated: 28/01/2020	12/18A	12/19E	12/20E	12/21E	
Adjusted P/E (x)	16.9	22.3	13.3	10.6	
Dividend yield (%)	3.46	4.14	4.99	5.28	
EV/EBITDA(R) (x)	9.11	10.4	7.48	6.26	
Adjusted EPS (€)	1.15	0.81	1.28	1.61	
Growth in EPS (%)	5.33	-29.1	57.9	25.5	
Dividend (€)	0.67	0.75	0.85	0.90	
Sales (€M)	573	631	776	973	
Underlying operat. profit ma	8.55	7.03	8.39	8.89	
Attributable net profit (€M)	26.6	18.7	32.0	43.4	
ROE (after tax) (%)	11.4	7.63	10.2	11.0	
Gearing (%)	17.6	52.7	40.4	36.4	
Company Valuation - Company Financials					



Sales by Geography

Consolidated P&L Accounts



Europe (43.0%) Americas (30.0%) Asia (25.0%) Other (2.0%)

12/18A 12/19E 12/20E

Valuation Summary

Benchmarks	Value	Weight
NAV/SOTP per share	€ 31.1	55%
Dividend Yield	€29.4	20%
DCF	€ 40.2	10%
P/E	€27.1	10%
P/Book	€ 15.2	5%
TARGET PRICE	€ 30.5	100%

Largest comparables

- Ackermans & van H...
- Wacker ChemieAkzoNobel
- Solvay
- Bolloré
- GBL

Sonae

Hal Trust

NAV/SOTP Calculation

Balance Sheet		12/18A	12/19E	12/2
Goodwill	€M	128	202	2
Total intangible	€M	158	204	:
Tangible fixed assets	€M	80.7	113	
Financial fixed assets	€M	13.1	15.0	2
WCR	€M	41.7	55.0	6
Other assets	€M	23.0	30.0	3
Total assets (net of short term liab.)	€M	324	421	(
Ordinary shareholders' equity	€M	237	253	
Quasi Equity & Preferred	€M			
Minority interests	€M	0.00	0.00	0
Provisions for pensions	€M	17.4	17.6	1
Other provisions for risks and liabilities	€M	0.50	1.00	5
Total provisions for risks and liabilities	€M	17.9	18.6	2
Tax liabilities	€M	-27.2	-30.0	-3
Other liabilities	€M	3.50	5.00	5
Net debt (cash)	€M	92.2	175	
Total liab. and shareholders' equity	€M	324	421	(
Capital Employed				
Capital employed after depreciation	€M	294	387	4
Profits & Risks Ratios				
ROE (after tax)	%	11.4	7.63	1
ROCE	%	11.6	7.81	9
Gearing (at book value)	%	17.6	52.7	4
Adj. Net debt/EBITDA(R)	х	1.54	3.05	1
Interest cover (x)	х	4.67	3.55	4
Valuation Ratios				
Reference P/E (benchmark)	x	16.9	22.3	1
Free cash flow yield	%	-2.69	1.47	7
P/Book	х	1.88	1.64	1
Dividend yield	%	3.46	4.14	4
EV Calculation				
Market cap	€M	447	416	4
+ Provisions	€M	17.9	18.6	2
+ Unrecognised acturial losses/(gains)	€M	0.00	0.00	0
+ Net debt at year end	€M	92.2	175	
+ Leases debt equivalent	€M	0.00	0.00	0
	€M	16.0	16.0	1
 Financial fixed assets (fair value) 	CM	4.00	4.00	4
 Financial fixed assets (fair value) + Minority interests (fair value) 	€M			
, ,	€M	545	597	Ę
+ Minority interests (fair value)		545 9.11	597 10.4	؛ 7

Analyst : Jorge Velandia, Changes to Forecasts : 28/01/2020.

consolidated F &L Accounts		12/18A	12/19E	12/20E
Sales	€M	573	631	776
Change in sales	%	7.56	10.1	23.0
Change in staff costs	%	33.9	11.5	20.4
EBITDA	€M	59.8	57.2	80.1
EBITDA(R) margin	%	10.4	9.06	10.3
Depreciation	€M	-10.8	-12.8	-15.0
Underlying operating profit	€M	48.1	42.4	61.6
Operating profit (EBIT)	€M	42.2	31.5	49.6
Net financial expense	€M	-10.6	-12.2	-15.3
of which related to pensions	€M	-0.30	-0.14	-0.22
Exceptional items & other	€M			
Corporate tax	€M	-5.08	-1.05	-2.80
Equity associates	€M	0.10	0.50	0.50
Minority interests	€M	0.00	0.00	0.00
Adjusted attributable net profit	€M	26.6	18.7	32.0
NOPAT	€M	34.0	30.3	43.8
Cashflow Statement				
EBITDA	€M	59.8	57.2	80.1
Change in WCR	€M	-22.5	-13.3	-5.00
Actual div. received from equity holdi	€M	0.00	0.50	0.50
Paid taxes	€M	-6.00	-1.05	-2.80
Exceptional items	€M			
Other operating cash flows	€M	-8.40	-5.00	-5.00
Total operating cash flows	€M	22.9	38.3	67.8
Capital expenditure	€M	-24.3	-20.0	-17.0
Total investment flows	€M	-90.3	-90.0	-87.0
Net interest expense	€M	-10.6	-12.2	-15.3
Dividends (parent company)	€M	-10.8	-15.6	-17.5
Dividends to minorities interests	€M	0.00	0.00	0.00
New shareholders' equity	€M	-10.2	0.00	100
Total financial flows	€M	-42.6	-38.0	62.4
Change in cash position	€M	-110	-89.7	43.3
Free cash flow (pre div.)	€M	-12.0	6.11	35.5
Per Share Data				
No. of shares net of treas. stock (year	Mio	23.1	23.0	27.0
Number of diluted shares (average)	Mio	23.2	23.0	25.0
Benchmark EPS	€	1.15	0.81	1.28
Restated NAV per share	€			
Net dividend per share	€	0.67	0.75	0.85

© 2020, AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information networks and not untrue or misleading at the time of publication, we make no representation that it is accurate or complete and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.